Evidence map›Paper›PMID 33413292›Full record

ArticleBMC urology2021

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.

Hideyuki Minagawa, Taketo Kawai, Akihiko Matsumoto, Katsuhiro Makino, Yusuke Sato, Kenji Nagasaka, Masami Tokura, Nao Tanaka, Eisaku Ito, Yuta Yamada and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Hideyuki MinagawaDepartment of Urology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Taketo KawaiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan. taketokawai@yahoo.co.jp.
Akihiko MatsumotoDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Katsuhiro MakinoDepartment of Urology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Yusuke SatoDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Kenji NagasakaDepartment of Rheumatology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Masami TokuraDepartment of Rheumatology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Nao TanakaDepartment of Rheumatology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Eisaku ItoDepartment of Pathology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Masaki NakamuraDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Daisuke YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Motofumi SuzukiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Takashi MurataDepartment of Urology, Ome Municipal General Hospital, 4-16-5, Higashiome Ome, Ome, Tokyo, 1980042, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
The University of Tokyo · JPOme Municipal General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough it is known that malignancies can be associated with dermatomyositis, there are few reports on dermatomyositis associated with prostate cancer with neuroendocrine differentiation. CASE PRESENTATION: A 63-year-old man visited our hospital due to pollakiuria. High levels of PSA and NSE were observed, and prostate biopsy revealed an adenocarcinoma with neuroendocrine differentiation. Multiple metastases to the lymph nodes, bones, and liver were identified, and androgen deprivation therapy (ADT) was started immediately. Following 2 weeks of treatment, erythema on the skin, and muscle weakness with severe dysphagia appeared. The patient was diagnosed with dermatomyositis, and high-dose glucocorticoid therapy was initiated. ADT and subsequent chemotherapy with etoposide and cisplatin (EP) were performed for prostate cancer, which resulted in decreased PSA and NSE and reduction of all metastases. After the initiation of EP therapy, dermatomyositis improved, and the patient regained oral intake function. Although EP therapy was replaced by docetaxel, abiraterone, and enzalutamide because of adverse events, no cancer progression was consistently observed. Dermatomyositis worsened temporarily during the administration of abiraterone, but it improved upon switching from abiraterone to enzalutamide and dose escalation of glucocorticoid.

conclusionsWe successfully treated a rare case of dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.

Indexed as

AdenocarcinomaDermatomyositisHumansMaleMiddle AgedNeuroendocrine CellsProstatic NeoplasmsAbirateroneADTDermatomyositisDocetaxelDysphagiaEnzalutamideEPGlucocorticoidNeuroendocrine differentiationProstate cancer

Identifiers

PMID33413292
PMCPMC7791876
OpenAlexW3120268231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.